List of Excipients in Branded Drug PEMAZYRE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Incyte Corporation	PEMAZYRE	pemigatinib	50881-026	CELLULOSE, MICROCRYSTALLINE	2040-10-03
Incyte Corporation	PEMAZYRE	pemigatinib	50881-026	MAGNESIUM STEARATE	2040-10-03
Incyte Corporation	PEMAZYRE	pemigatinib	50881-026	SODIUM STARCH GLYCOLATE TYPE A POTATO	2040-10-03

Pemazyre Excipient Strategy and Commercial Opportunities: Formulation, Supply Chain, Lifecycle Management, and Generic Risk

Last updated: August 9, 2026

Pemazyre, whose active ingredient is pemigatinib, is a small-molecule, orally administered FGFR inhibitor marketed by Incyte. Its commercial formulation is a low-dose immediate-release tablet available in 4.5 mg, 9 mg, and 13.5 mg strengths. The current product strategy depends on dose flexibility, chronic oral administration in selected patients, global excipient acceptability, and protection of a specialized oncology product with limited but commercially valuable patient populations.

The most attractive excipient opportunities are not high-volume commodity substitution. They are supplier and formulation opportunities involving direct-compression performance, low-dose content uniformity, dissolution control, moisture management, tablet robustness, global regulatory acceptance, and future lifecycle products such as capsules, dispersible tablets, pediatric formulations, or combination packs.

What is Pemazyre and how does its formulation generate commercial value?

Pemazyre is an oral kinase inhibitor containing pemigatinib. The FDA approved it for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement, as detected by an FDA-approved test. The product is also approved for adults with relapsed or refractory myeloid or lymphoid neoplasms with an FGFR1 rearrangement [1].

Pemazyre is supplied as immediate-release tablets in three strengths:

Product attribute	Commercial relevance
Active ingredient	Pemigatinib
Dosage form	Immediate-release tablet
Strengths	4.5 mg, 9 mg, 13.5 mg
Administration	Oral, once daily on a 14-days-on, 7-days-off schedule in the principal cholangiocarcinoma regimen
Primary commercial use	Molecularly selected oncology treatment
Manufacturer	Incyte Corporation
Regulatory pathway	New drug application, with an accelerated-approval history for selected indications
Patient selection	FGFR2 or FGFR1 genomic alteration, depending on indication

The low active-pharmaceutical-ingredient load creates a classic content-uniformity and blend-segregation challenge. The formulation must distribute a small quantity of pemigatinib consistently through a larger excipient matrix while maintaining acceptable hardness, friability, disintegration, and dissolution.

The dosing schedule also creates a commercial distinction. Patients receive repeated treatment cycles, but not continuous daily dosing. That reduces monthly tablet consumption relative to a seven-day-per-week regimen while preserving recurring demand for specialty oncology distribution.

What excipients are used in Pemazyre tablets?

The FDA prescribing information identifies the tablet core as containing microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. The film coating contains hypromellose, titanium dioxide, talc, and iron oxide-based colorants, depending on the strength and product presentation [1].

Excipient class	Reported or relevant material	Likely formulation function
Diluent and compression aid	Microcrystalline cellulose	Bulk, compactibility, tablet hardness
Disintegrant	Sodium starch glycolate	Water uptake and tablet breakup
Lubricant	Magnesium stearate	Ejection and prevention of sticking
Film former	Hypromellose	Protective and cosmetic coating
Opacifier or whitening agent	Titanium dioxide	Appearance and opacity
Anti-tacking and processing aid	Talc	Coating performance and surface properties
Colorant	Iron oxide	Strength identification and product differentiation

The listed excipient system is conventional for an immediate-release tablet. Its commercial value lies in execution rather than novelty. For a low-dose kinase inhibitor, the critical technical variables include:

• Pemigatinib particle-size distribution.
• Blend uniformity at low drug loading.
• Lubricant mixing time and magnesium-stearate sensitivity.
• Disintegrant grade and swelling performance.
• Compression-force operating range.
• Film-coating weight gain and color consistency.
• Dissolution performance across pH conditions.
• Stability under humidity and temperature stress.

A supplier that can offer consistent low-substitution-variability excipients, strong lot-to-lot documentation, and global regulatory support has a stronger commercial position than a supplier competing only on price.

Which excipient suppliers and technologies have the strongest opportunity?

The highest-value opportunities are concentrated in four areas.

Low-dose direct-compression systems

Pemigatinib tablets require reliable content uniformity across multiple strengths. Co-processed excipients combining a compressible filler with a disintegrant or flow aid could reduce segregation and improve manufacturing robustness.

Potential technologies include:

• Co-processed microcrystalline cellulose systems.
• Spray-dried lactose or alternative directly compressible fillers.
• Silicified microcrystalline cellulose.
• Improved-flow excipient blends for low-dose APIs.
• Excipient systems designed for narrow tablet-weight variation.

A replacement excipient would need to preserve the product’s dissolution profile and support bioequivalence. A technically superior system could have value in contract manufacturing, regional product transfer, or post-approval manufacturing changes.

Functional disintegrants

Sodium starch glycolate is established and cost-effective, but its performance can vary with grade, substitution level, particle size, and moisture. Alternative or enhanced disintegrant systems could provide faster and more reproducible tablet breakup.

Commercial targets include:

• Crospovidone.
• Croscarmellose sodium.
• Low-substituted hydroxypropyl cellulose.
• Co-processed disintegrant blends.
• Disintegrants with improved performance at lower concentrations.

The opportunity is strongest where a manufacturer needs better dissolution control without increasing tablet size.

Film-coating systems

The three tablet strengths require reliable visual differentiation. A ready-to-use film-coating system can reduce batch complexity and improve coating uniformity.

Relevant supplier offerings include:

• Pre-formulated hypromellose coating systems.
• Low-moisture coating systems.
• Pigment systems compatible with global colorant restrictions.
• Coatings that reduce tablet friability and improve handling.
• Low-temperature coating systems for moisture-sensitive formulations.

The main barrier is regulatory change control. A coating supplier must support comparative dissolution, stability, extractables and leachables where relevant, and updated chemistry, manufacturing, and controls documentation.

Lubrication and anti-sticking technologies

Magnesium stearate remains a standard lubricant, but over-lubrication can slow wetting and dissolution. Alternative lubricants or optimized blending processes may improve manufacturability.

Potential products include:

• Sodium stearyl fumarate.
• Stearic-acid-based alternatives.
• Engineered magnesium-stearate grades.
• Continuous lubrication systems.
• Process analytical technology for lubricant distribution.

The commercial case depends on proving that the substitute does not alter bioavailability, dissolution, tablet strength, or long-term stability.

What formulation patents protect Pemazyre and where are the commercial barriers?

Pemazyre’s principal intellectual-property value is expected to reside in the pemigatinib compound, pharmaceutical compositions, methods of treatment, and manufacturing processes. The compound patent estate is more important commercially than the conventional excipient system disclosed in the marketed tablet.

Public FDA and patent records should be evaluated across four categories:

IP category	Relevance to Pemazyre
Compound patents	Core protection for pemigatinib and related chemical matter
Composition patents	May cover pharmaceutical compositions, dosage forms, or selected excipient combinations
Method-of-use patents	May cover treatment of FGFR-altered cholangiocarcinoma or hematologic malignancies
Manufacturing patents	May cover intermediates, synthetic routes, purification, or crystalline forms

The standard tablet excipients identified in the FDA label are widely used and are unlikely, by themselves, to create a meaningful barrier to generic development. A commercial challenger would more likely design around the excipient system while matching the reference product’s critical quality attributes.

The most important technical barriers are:

• Low-dose blend uniformity.
• Comparable dissolution across the approved strengths.
• Stability of the active ingredient and dosage form.
• Demonstration of bioequivalence.
• Production of three strengths without excessive manufacturing complexity.
• Control of polymorphism, particle size, and API solid-state properties.
• Regulatory documentation for a specialty oncology product.

When does Pemazyre lose exclusivity and what is the generic-entry risk?

Pemazyre’s generic-entry timing depends on several separate protections:

1. FDA regulatory exclusivity.
2. Listed U.S. patents.
3. Patent-term adjustment or extension.
4. Pediatric exclusivity, if granted.
5. Paragraph IV challenges and litigation outcomes.
6. Settlement agreements or licenses.
7. Foreign patent terms and national procedures.

The product’s cholangiocarcinoma approval was based on an accelerated-approval framework tied to overall response rate and duration of response in a molecularly selected population [1]. FDA regulatory exclusivity and patent protection must be analyzed separately because an ANDA applicant may challenge listed patents before their expiration.

Paragraph IV exposure

A generic applicant can file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed. In that event, the NDA holder may file patent litigation, potentially triggering a 30-month stay under the Hatch-Waxman framework [2].

The commercial risk is moderate rather than equivalent to a mass-market oral drug because:

• Pemazyre is used in biomarker-selected cancers.
• The addressable population is smaller than for broad oncology products.
• Multiple tablet strengths increase manufacturing and inventory requirements.
• Clinical demand may be concentrated through specialty pharmacies and oncology centers.
• The product’s price creates an incentive for generic entry despite the smaller volume.

The highest-risk generic scenario is an at-risk launch after a successful Paragraph IV challenge or a negotiated launch date before the full expiry of all relevant patents. The lower-risk scenario is delayed entry after compound and use patents expire, with generic competition initially limited by modest market size and manufacturing complexity.

What regulatory status and Orange Book issues affect Pemazyre?

Pemazyre is listed in FDA drug databases under NDA 214801. The Orange Book analysis should identify:

• All listed patents.
• Patent-use codes.
• Expiration dates.
• Pediatric exclusivity.
• Any withdrawn or delisted patents.
• Whether a listed patent covers the approved use, formulation, or active ingredient.

For oncology products, method-of-use listings can materially affect generic labeling. A generic applicant may seek a section viii “skinny label” that omits patented indications, although the feasibility depends on the scope of the listed use code and the remaining unpatented indications [2].

The practical regulatory question is whether the generic can market pemigatinib for an unpatented use without inducing infringement of a patented oncology indication. That analysis requires the precise Orange Book use code and the proposed generic label.

What lifecycle-management opportunities exist for Pemazyre?

Pemazyre’s current immediate-release tablet leaves several potential lifecycle options.

Alternative oral dosage forms

A capsule, orally disintegrating tablet, mini-tablet, or dispersible tablet could target patients with dysphagia, treatment-related nausea, or difficulty swallowing. Any reformulation would need to address:

• Dose accuracy.
• Rapid and consistent dissolution.
• Stability under humidity.
• Patient acceptability.
• Packaging requirements.
• Bioequivalence or clinical bridging.

An orally disintegrating formulation could create value in supportive-care settings, but the commercial opportunity is constrained by the small patient population and the ability of current tablets to meet routine administration needs.

Pediatric and rare-disease formulations

The FGFR1-rearranged hematologic indication is rare. A lower-strength tablet or liquid formulation could support pediatric investigation or patients requiring dose reduction. A liquid product would introduce new excipient requirements, including:

• Suspending agents.
• Preservatives.
• Sweeteners.
• Flavor systems.
• pH control.
• Container-closure compatibility.

Liquid formulations also create higher microbiological and stability risks than the existing tablet.

Fixed-dose or regimen-oriented packaging

Pemazyre is administered in cycles. Calendar blister packs could reduce dosing errors and improve adherence. Commercial value could come from packaging rather than new excipient chemistry.

A cycle pack could contain:

• The correct number of tablets for the on-treatment period.
• Clearly marked off-treatment days.
• Strength-specific dose instructions.
• Integrated patient-support materials.

This approach is less exposed to formulation-development risk than a new dosage form.

Excipient substitution for resilience

A post-approval change could reduce dependence on a single supplier or improve manufacturing economics. The strongest candidates are excipients with multiple qualified sources and established compendial status.

A substitution strategy should prioritize:

1. Microcrystalline cellulose.
2. Sodium starch glycolate.
3. Magnesium stearate.
4. Film-coating materials.
5. Colorants and pigments.

The business case is strongest when the change improves supply continuity without changing tablet weight, dissolution, or appearance.

How does Pemazyre compare with competing FGFR inhibitors?

Pemazyre competes primarily with other targeted treatments for molecularly defined cholangiocarcinoma and FGFR-altered disease. Relevant competitors include Truseltiq, whose active ingredient is infigratinib, and broader oncology agents used in biomarker-selected treatment pathways.

Commercial factor	Pemazyre	Infigratinib products
Therapeutic class	FGFR inhibitor	FGFR inhibitor
Dosage form	Immediate-release tablet	Oral capsule formulation for the former U.S. indication
Biomarker focus	FGFR2 alterations in cholangiocarcinoma; FGFR1 rearrangements in hematologic disease	Primarily FGFR2-altered cholangiocarcinoma
Excipient opportunity	Tablet compression, low-dose uniformity, coating, supply resilience	Capsule-fill systems, powder flow, capsule-shell and stability systems
Differentiation	Broader FGFR1 and FGFR2 commercial positioning	More concentrated cholangiocarcinoma positioning
Generic complexity	Multiple strengths and tablet matching	Capsule formulation and indication-specific regulatory issues

The competitive advantage of Pemazyre’s tablet platform is manufacturing simplicity relative to a complex controlled-release or injectable product. Its disadvantage is that standard immediate-release tablets are easier for generic manufacturers to replicate than novel delivery systems.

What revenue exposure and commercial opportunities exist for excipient companies?

Pemazyre is a specialty product, so the commercial opportunity for an excipient supplier is based on strategic value per product rather than large unit volume.

Revenue exposure can arise through:

• Primary excipient supply to Incyte or its contract manufacturer.
• Second-source qualification.
• Regional manufacturing transfers.
• Reformulation programs.
• Generic development after patent barriers weaken.
• Packaging and calendar-blister systems.
• Analytical and regulatory support.
• Continuous manufacturing or process-optimization projects.

The best target customers are not only the NDA holder. They include:

• Contract development and manufacturing organizations.
• Generic pharmaceutical companies preparing ANDA filings.
• Excipient manufacturers with direct-compression platforms.
• Film-coating suppliers.
• Specialty packaging companies.
• Analytical laboratories supporting dissolution and stability work.

The market is unlikely to support a standalone high-volume excipient franchise based solely on Pemazyre. It can support a platform sale if the same excipient system is applicable to other low-dose kinase inhibitors, oncology tablets, or rare-disease products.

What manufacturing and intellectual-property barriers should investors assess?

A commercial diligence review should separate barriers that are legally enforceable from those that are merely operational.

Legal barriers

• Compound patent expiry.
• Composition and formulation patents.
• Method-of-use patents.
• Patent-term adjustment.
• Paragraph IV litigation.
• Settlement terms.
• Foreign patent coverage.
• Regulatory exclusivity.

Operational barriers

• API availability.
• Low-dose blending capability.
• Multi-strength tablet production.
• Specialized analytical methods.
• Stability data requirements.
• Specialty-pharmacy distribution.
• Biomarker-driven demand forecasting.
• Qualified supplier networks.

A conventional excipient substitution is unlikely to provide durable exclusivity unless protected by a patentable formulation or process innovation. Its value is more likely to come from lower cost, reduced variability, supply assurance, or improved patient usability.

Key Takeaways

• Pemazyre is a low-dose immediate-release pemigatinib tablet marketed in 4.5 mg, 9 mg, and 13.5 mg strengths.
• The labeled excipient system is conventional: microcrystalline cellulose, sodium starch glycolate, magnesium stearate, hypromellose, titanium dioxide, talc, and iron oxide-based colorants.
• The highest-value formulation issue is low-dose content uniformity combined with reliable immediate-release dissolution.
• Direct-compression excipient systems, functional disintegrants, film coatings, and lubrication technologies offer the clearest supplier opportunities.
• The marketed excipient combination is unlikely to be the principal generic barrier. Compound, method-of-use, composition, and manufacturing patents are more important.
• Generic-entry risk will depend on the complete Orange Book listing, patent expiry, Paragraph IV activity, litigation, and any settlement agreement.
• Lifecycle opportunities include alternative oral dosage forms, cycle-based blister packaging, supply-chain-driven excipient substitutions, and lower-strength or pediatric formulations.
• Excipient companies should pursue Pemazyre as part of a broader low-dose oncology formulation platform rather than as a standalone volume opportunity.

FAQs

Can Pemazyre be reformulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could address swallowing difficulty, but development would require control of taste, dose uniformity, tablet friability, moisture sensitivity, dissolution, and bioequivalence.

Which Pemazyre excipient is most important for tablet performance?

Microcrystalline cellulose is central to tablet compactibility and weight control. Sodium starch glycolate is critical to disintegration, while magnesium stearate requires careful optimization because excessive lubrication can impair wetting and dissolution.

Could an excipient change create new patent protection for Pemazyre?

Potentially, but only if the new formulation or process has novelty, non-obviousness, and a defensible technical effect. Replacing one conventional compendial excipient with another would generally provide weak patent protection.

Is Pemazyre suitable for a liquid oral formulation?

Technically, yes. A liquid formulation would require suspension or solution development, preservative control, palatability work, container-closure studies, and stability testing. The commercial case depends on pediatric use, swallowing limitations, and demand volume.

What is the most realistic generic launch scenario for Pemazyre?

The most realistic scenario is a conventional immediate-release tablet generic launched after resolution or expiration of the relevant compound and use patents. A Paragraph IV filing could move the launch date forward, but the outcome would depend on Orange Book listings, litigation, and any negotiated settlement.

References

1. U.S. Food and Drug Administration. (2023). Pemazyre (pemigatinib) prescribing information. Incyte Corporation.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (1984). Drug Price Competition and Patent Term Restoration Act of 1984. U.S. Department of Health and Human Services.

4. Incyte Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

5. U.S. Food and Drug Administration. (2022). Project Orbis: Pemazyre approval for FGFR2 fusion or rearrangement-positive cholangiocarcinoma. U.S. Department of Health and Human Services.